Search

Your search keyword '"Malinverno F"' showing total 81 results

Search Constraints

Start Over You searched for: Author "Malinverno F" Remove constraint Author: "Malinverno F"
81 results on '"Malinverno F"'

Search Results

1. OC.05.7: CHOLESTASIS IMPACTS ON PERFORMANCE OF NON INVASIVE TESTS FOR RULING OUT HIGH-RISK ESOPHAGEALVARICES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND COMPENSATED ADVANCED CHRONIC LIVER DISEASE

2. Survey on hepatic sarcoidosis in Italy

4. Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

5. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

6. Long‐term outcomes of direct acting antivirals in post‐transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis

7. Predictors of Serious Adverse Event and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis under Obeticholic Acid

8. Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group

9. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: A real-life strategy

13. Pre-treatment risk stratification in primary biliary cholangitis: A predictive model to guide first-line combination therapy

14. A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude?

15. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants

16. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways

17. PC.01.1 MANAGEMENT OF BILIARY ANASTOMOTIC STRICTURE AFTER LIVER TRANSPLANTATION (BASALT STUDY): RESULTS OF A NATIONAL SURVEY IN ITALY

19. P0903 : Slow HCV kinetics following sofosbuvir + ribavirin administration in real-life setting of liver transplant recipients with severe recurrent hepatitis C

20. LP51 : Treatment of severe HCV recurrence after liver transplantation with sofosbuvir based regimen: Results of the aisf-sofolt Italian compassionate use program

21. Slow achievement of HCV-RNA undetectability in cirrhotic patients treated with sofosbuvir+ribavirin: possible clinical implications in the liver transplant list management

23. Slow achievement of HCV-RNA undetectability in cirrhotic patients treated with sofosbuvir + ribavirin: possible clinical implications in the liver transplant list management

24. Preventive administration of ursodeoxycholic acid after liver transplantation for primary biliary cholangitis prevents disease recurrence and prolongs graft survival

25. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

26. Real-world experience with obeticholic acid in patients with primary biliary cholangitis

27. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

28. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

29. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways

30. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis

31. Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach

32. Primary Sclerosing Cholangitis: Burden of Disease and Mortality Using Data from the National Rare Diseases Registry in Italy

33. Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group

34. Comprehensive review of autoantibodies in patients with hyper-IgM syndrome

35. From pathogenesis to novel therapies in the treatment of primary biliary cholangitis

36. Accuracy of liver stiffness measurement in assessing liver fibrosis in naive patients with primary biliary cholangitis

37. FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study

38. THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis

39. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score

40. A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude?

41. Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis

42. Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach

43. DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis

44. Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid.

45. Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach.

46. Real-world experience with obeticholic acid in patients with primary biliary cholangitis.

47. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.

48. Primary Sclerosing Cholangitis: Burden of Disease and Mortality Using Data from the National Rare Diseases Registry in Italy.

49. Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival.

50. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.

Catalog

Books, media, physical & digital resources